Kleinerman, M.D. / Kleinerman Current Advances in Osteosarcoma

1. Auflage 2014
ISBN: 978-3-319-04843-7
Verlag: Springer International Publishing
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, Band 804, 359 Seiten, eBook

Reihe: Advances in Experimental Medicine and Biology

Current Advances in Osteosarcoma edited by Dr. Eugenie S. Kleinerman summarizes molecular and genetic characteristics, new therapeutic ideas, and biological characteristics that have been uncovered in the past 10 years. Osteosarcoma is an aggressive malignant neoplasm and it is also the most common histological form of bone cancer. It accounts for approximately 56% of new bone tumors, making it the most primary malignant bone tumor in children and adolescents. The lungs are the most common site of metastases and once osteosarcoma spreads to the lungs, it is very difficult to treat. To improve the outcome of this disease, the biology of osteosarcoma needs to be better understood. There are numerous investigators around the world who have made seminal discoveries about the important molecular pathways and genetic alterations that contribute to the development and metastases of osteosarcoma. Other investigators have proposed novel therapeutic strategies including some based on the molecular and genetic phenotype of the disease. Current Advances in Osteosarcoma summarizes all of these new discoveries in one singular text, which will help move the field forward.

Zielgruppe

Research

Autoren/Hrsg.

Kleinerman, M.D., Eugenie S.

Kleinerman, M. D.

Inhaltsverzeichnis

Historical Perspective on the Introduction and Use of Chemotherapy for the Treatment of Osteosarcoma.- Wnt Signaling in Osteosarcoma.- Receptor Tyrosine Kinases in Osteosarcoma: Not Just the Usual Suspects.- Understanding the Role of Notch in Osteosarcoma.- Developmental Pathways Highjacked by Osteosarcoma.- MicroRNAs in Osteosarcomagenesis.- RECQ DNA Helicases and Osteosarcoma.- Autophagy in Osteosarcoma.- HER-2 Involvement in Osteosarcoma.- Role of Ezrin in Osteosarcoma Metastasis.- Participation of the Fas/FasL Signaling Pathway and the Lung Microenvironment in the Development of Osteosarcoma Lung Metastases.- Zebrafish as a Model for Human Osteosarcoma.- Using Canine Osteosarcoma as a Model to Assess Efficacy of Novel Therapies: Can Old Dogs Teach Us New Tricks?.- Oncolytic Viruses for Potential Osteosarcoma Therapy.- IL-11Ra: A Novel Target for the Treatment of Osteosarcoma.- Bone-seeking Radiopharmaceuticals as Targeted Agents of Osteosarcoma: Samarium-153-EDTMP and Radium-223.- Muramyl Tripeptide-phophatidyl Ethanolamine Encapsulated in Lipomes (L-MTP-PE) in the Treatment of Osteosarcoma.- Genetically Modified T-cell Therapy for Osteosarcoma.- Natural Killer Cells for Osteosarcoma.

Über Autor(innen)

Eugenie S. Kleinerman, M.D. is Professor and Head of the Division of Pediatrics, the first women Division Head at MD Anderson Cancer Center. She is board certified in pediatrics, holds the Mosbacher Pediatrics Chair and is also a Professor of Cancer Biology. Dr. Kleinerman is internationally recognized for her scientific and clinical expertise in sarcomas, particularly osteosarcoma. She pioneered the use of a unique immunotherapy agent liposome-encapsulated MTP-PE, for children with unresponsive relapsed osteosarcoma lung metastases. Dr. Kleinerman has served on numerous NCI study sections and was a prior member of an FDA advisory panel. She has authored over 177 articles and 21 book chapters and has received over 2900 citations. In 2006, her achievements were recognized by her alma mater, Duke University Medical Center, where she received the Distinguished Medical Alumnus Award. She is the 2009 recipient of the Faculty Achievement Award in Clinical Research.